The 2020 release of the WHO Classification of Soft Tissue and Bone Tumors, 5th edition, contains several changes driven by new knowledge in the field. These include reclassification of some entities, refinement of risk classification systems, and the inclusion of novel disease processes, many of which are driven by recurrent gene fusions. The most notable changes are described here.
Citations
Citations to this article as recorded by
Chondroblastic Osteosarcoma in an Adolescent: Are Conventional Biopsy Techniques Just Scratching the Surface? Neeraj Kumar Dhiman, Arjun Mahajan, Trupti Jain, Ajit Kumar Vishwakarma, Rahul Agrawal Indian Journal of Otolaryngology and Head & Neck Surgery.2025; 77(2): 1023. CrossRef
Radiomics and Deep Learning Model for Benign and Malignant Soft Tissue Tumors Differentiation of Extremities and Trunk Miaomiao Yang, Xiuming Zhang, Jiyang Jin Academic Radiology.2025;[Epub] CrossRef
Conference on Challenges in Sarcoma (CCS) 2024 Expert Opinions on Non-Evidence-based Management Aspects Silvia Hofer, Chantal Pauli, Beata Bode, Sylvie Bonvalot, Christina Fotopoulou, Hans Gelderblom, Rick Haas, Jendrik Hardes, Peter Hohenberger, Jens Jakob, Wolfgang G. Kunz, Andreas Leithner, Bernadette Liegl-Atzwanger, Lars Lindner, Aisha Miah, Peter Reic European Journal of Cancer.2025; : 115368. CrossRef
Management of a rapidly enlarging supraclavicular mass of unknown aetiology Mateo Cukman, Karla Luzaic, Kristina Krstanovic, Sinisa Stevanovic BMJ Case Reports.2024; 17(2): e255774. CrossRef
Pathogenetic and molecular classifications of soft tissue and bone tumors: A 2024 update Andrei Ionut Patrichi, Simona Gurzu Pathology - Research and Practice.2024; 260: 155406. CrossRef